TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04023721

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inarigivir soproxil
Description: Inarigivir soproxil 200 mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inarigivir soproxil
Description: Inarigivir soproxil 200 mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inarigivir soproxil
Description: Inarigivir soproxil 200 mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nucleoside/nucleotide (NUC) analogue inhibitors
Description: Continuation of prestudy NUC therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nucleoside/nucleotide (NUC) analogue inhibitors
Description: Continuation of prestudy NUC therapy
Study: NCT02745262

Intervention type: OTHER
Intervention: Collect retrospectively the follow-up data
Description: Collect retrospectively the follow-up data. Each patient is called in order to request data authorization, to complete and track information.

Intervention type: OTHER
Intervention: Collect retrospectively the follow-up data
Description: Collect retrospectively the follow-up data. Each patient is called in order to request data authorization, to complete and track information.
Study: NCT01894373

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adoptive Immunotherapy
Description: Biological: in vitro expanded Cytokine Induced Killer (CIK) cells Procedure: Infusion of autologous CIK cells

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CIK
Study: NCT02647320

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin 100 mg
Description: Two sitagliptin 50 mg tablets, over-encapsulated to provide a once-daily dose of 100 mg, for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-8500a 25mg
Description: DS-8500a 25mg tablet for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-8500a 25mg
Description: DS-8500a 25mg tablet for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-8500a 25mg
Description: DS-8500a 25mg tablet for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Tablet
Description: Placebo matching DS-8500a tablet for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Tablet
Description: Placebo matching DS-8500a tablet for oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Tablet
Description: Placebo matching DS-8500a tablet for oral administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Tablet
Description: Placebo matching DS-8500a tablet for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Capsule
Description: Placebo matching sitagliptin over-capsule for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Capsule
Description: Placebo matching sitagliptin over-capsule for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Capsule
Description: Placebo matching sitagliptin over-capsule for oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Capsule
Description: Placebo matching sitagliptin over-capsule for oral administration
Study: NCT02049151

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tecemotide
Description: Tecemotide injection will be administered once weekly subcutaneously at a dose of 806 microgram up to Week 8 and from Week 14, every 6 weeks until end-of-trial, or until NSCLC progression.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo injection will be administered once weekly subcutaneously up to Week 8 and from Week 14, every 6 weeks until end-of-trial, or until NSCLC progression.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (CPA)
Description: CPA injection will be administered as a single intravenous infusion at a dose of 300 milligram per square meter (mg/m\^2) (to a maximum of 600 mg) 3 days before the first injection of tecemotide.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline (sodium chloride)
Description: Matching placebo (saline) injection will be administered as a single intravenous (0.9 percent \[%\] sodium chloride) infusion 3 days before the first injection of tecemotide-matching placebo.
Study: NCT00128076

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: All-Arthroscopic repair
Description: joint techniques and repair are both performed entirely through the arthroscope

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mini-open repair
Description: repair is performed though a small incision and the arthroscope can be used to address problems within the joint (as per traditional diagnostic procedures)
Study: NCT00107120

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Description: Escitalopram 10mg per day for three weeks, 10-20mg per day for up to the remaining 5 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo once daily for up to 8 weeks
Study: NCT02203123

Intervention type: DEVICE
Group type: OTHER
Intervention: Ultrasound

Intervention type: DRUG
Group type: OTHER
Intervention: normal saline
Study: NCT04302454

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Radiotherapy

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Description: Radiotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprorelin
Description: Hormonal therapy
Study: NCT03368911

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oral/Nasal Endotracheal Tube, Reinforced (Covidien)
Description: Use Oral/Nasal Endotracheal Tube, Reinforced (Covidien) for endotracheal intubation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TaperGuard oral tracheal tube (Covidien)
Description: Use TaperGuard oral tracheal tube (Covidien) for endotracheal intubation
Study: NCT00344474

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PRE-Venture: Personality Risk Education
Description: Motivational and Cognitive-Behavioural interventions targeting four personality risk factors for substance misuse. Two, 90-minute group sessions conducted at school with personality-matched peers and trained psychologists/councellors and co-facilitators.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PRE-Venture: Personality Risk Education
Description: Motivational and Cognitive-Behavioural interventions targeting four personality risk factors for substance misuse. Two, 90-minute group sessions conducted at school with personality-matched peers and trained psychologists/councellors and co-facilitators.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PRE-Venture: Personality Risk Education
Description: Motivational and Cognitive-Behavioural interventions targeting four personality risk factors for substance misuse. Two, 90-minute group sessions conducted at school with personality-matched peers and trained psychologists/councellors and co-facilitators.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PRE-Venture: Personality Risk Education
Description: Motivational and Cognitive-Behavioural interventions targeting four personality risk factors for substance misuse. Two, 90-minute group sessions conducted at school with personality-matched peers and trained psychologists/councellors and co-facilitators.
Study: NCT03442985

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palovarotene 2.5 mg
Description: Subjects received a weight-adjusted dose equivalent of 2.5 mg palovarotene, once daily, for up to 24 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palovarotene 5.0 mg
Description: Subjects received a weight-adjusted dose equivalent of 5.0 mg palovarotene, once daily, for up to 24 months.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects received placebo, once daily, for up to 24 months.
Study: NCT03740594

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: KMC
Description: Neonates were subjected to either daily KMC for 60 minutes, daily KMC for 120 minutes or conventional care (controls) for at least 7 days.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: KMC
Description: Neonates were subjected to either daily KMC for 60 minutes, daily KMC for 120 minutes or conventional care (controls) for at least 7 days.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: KMC
Description: Neonates were subjected to either daily KMC for 60 minutes, daily KMC for 120 minutes or conventional care (controls) for at least 7 days.
Study: NCT02980237

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: eHealth_additional support
Description: An e-learning education program whose audiovisual content will be implemented. Nine audiovisual e-Health program will be composed of nine video classes addressing the following topics: 1) musculoskeletal health, 2) healthy diet and 3) mental health were identified through focus group. A communication tool will be adopted is the Moodle environment. All the participants will be able to whipping the web platform and questions regarding access and navigation are answered by e-mail. All participants will be monitored, as viewing the videos, and whenever it is identified that the participants not accessed and lack of interest of reasons. A team of tutors will be responsible for online support providing reinforcing stimuli and clarifying any questions (intervention group) on the content.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: eHealth_program
Description: The comparative group will receive the same eHealth education program that intervention group. But the comparative group will receive only audiovisuals without additional support. .
Study: NCT00362453

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tai Chi versus Attention Control
Description: 60 minutes, twice a week for 12 weeks.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Tai Chi versus Attention Control
Description: 60 minutes, twice a week for 12 weeks.
Study: NCT02800577

Intervention type: DEVICE
Group type: OTHER
Intervention: General Practitioner Emotional Test Battery (GP-ETB)
Description: The GP-ETB (Class I Medical Device) comprises three computer tasks. In the first task, the 'Emotional Categorisation Task' patients are given forty words that might be used to describe them and indicate whether they would 'like' or 'dislike' to be described by a particular word. In the 'Facial Expression Recognition Task' patients are asked to judge whether a briefly displayed face is expressing one of six emotions. In the final task, the 'Emotional Recall Task', the patient should recall as many words as they can from the series of words that were presented in the first task. The patients perform these tasks once before antidepressant treatment and again seven days after treatment begins.
Study: NCT02451241

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: electroacupuncture

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: acupuncture
Description: electroacupuncture
Study: NCT00534573

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amisulpride, Moclobemide
Description: Amisulpride 400 mg/d; Moclobemide 300 mg/d every medication for 2 week aith 2 week washout

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amisulpride, Moclobemide
Description: Amisulpride 400 mg/d; Moclobemide 300 mg/d every medication for 2 week aith 2 week washout
Study: NCT01688674

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 10% dextrose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10% dextrose
Study: NCT01954381

Intervention type: DEVICE
Group type: OTHER
Intervention: transthoracic echocardiographic

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transthoracic echocardiographic

Intervention type: DEVICE
Group type: OTHER
Intervention: Doppler ultrasound.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Doppler ultrasound.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: blood samples

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blood samples
Study: NCT01465204

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Total Sanitation and Sanitation Marketing
Description: Total Sanitation and Sanitation Marketing (TSSM) program is designed to promote demand for and supply of improved sanitation. On the demand side, it includes Community-Led Total Sanitation (CLTS). On the supply side, TSSM incorporates sanitation marketing interventions. Both CLTS and sanitation marketing draw heavily on the behavior-change communication and social marketing approaches that have been well developed in other sectors. The basic TSSM approach also builds sustainability and scalability through the strengthening of the national level sanitation sector enabling environment.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Total Sanitation and Sanitation Marketing
Description: Total Sanitation and Sanitation Marketing (TSSM) program is designed to promote demand for and supply of improved sanitation. On the demand side, it includes Community-Led Total Sanitation (CLTS). On the supply side, TSSM incorporates sanitation marketing interventions. Both CLTS and sanitation marketing draw heavily on the behavior-change communication and social marketing approaches that have been well developed in other sectors. The basic TSSM approach also builds sustainability and scalability through the strengthening of the national level sanitation sector enabling environment.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Scaling Up Handwashing Behavior Change
Description: The Handwashing with soap (HWWS) behavior change program expands and improves existing hygiene behavior change efforts with new and innovative promotional approaches in order to generate widespread and sustained improvement in handwashing with soap practices. These approaches include social marketing to deliver handwashing messages; broad and inclusive partnerships with government, private commercial marketing channels, and concerned consumer groups and NGOs.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Scaling Up Handwashing Behavior Change
Description: The Handwashing with soap (HWWS) behavior change program expands and improves existing hygiene behavior change efforts with new and innovative promotional approaches in order to generate widespread and sustained improvement in handwashing with soap practices. These approaches include social marketing to deliver handwashing messages; broad and inclusive partnerships with government, private commercial marketing channels, and concerned consumer groups and NGOs.
Study: NCT03509233

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Q-SRP
Description: Quadrant scaling and root planing under local anesthesia using ultrasonic devices (Piezon-Master, EMS) and Gracey curettes (Hu-Friedy) within four sessions in intervals of 1 week

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FMS
Description: Full mouth scaling and rootplaning under local anesthesia using ultrasonic devices (Piezon-Master, EMS) and Gracey curettes (Hu-Friedy) within 24 hours

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FMD
Description: Full mouth scaling and rootplaning under local anesthesia using ultrasonic devices (Piezon-Master, EMS) and Gracey curettes (Hu-Friedy) within 24 hours with additional disinfection using 0.2% chlorhexidine (mouth rinsing and tonsil spray), subgingival application of 1% chlorhexidine gel and 2 months postoperative home care using chlorhexidine 0.2% (rinse and spray)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FMDP
Description: FMD protocol (see FMD arm) with additional use of subgingival airpolishing (Air Flow, EMS) using Erythritol powder (Air-Flow Plus powder, EMS) for 20 seconds per tooth
Study: NCT01386060

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mindfulness Meditation Training
Description: One-on-one mindfulness meditation training, 6 weeks, 1 1/2 hour training once per week, 30-45 min at-home practice per day.
Study: NCT04123834

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Patella tendon & bone block autograft + press-fit femoral technique
Description: Implantless Arthroscopic ACL reconstruction using press-fit femoral technique The investigator's study uses the press-fit graft fixation technique by Edgar Michael. A midline skin incision was made that extends from inferior pole of patella up to anterior tibial tuberosity. Patella tendon with tibial tuberosity bone block were harvested, patella bone was left intact. The tendon was fixed together with non-absorbable suture.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arthroscopic ACL reconstruction
Description: Arthroscopic ACL reconstruction with implant (using hamstring autograft fixed with bioscrew and endo-button)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arthroscopic ACL reconstruction
Description: Arthroscopic ACL reconstruction with implant (using hamstring autograft fixed with bioscrew and endo-button)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hamstring tendon autograft + implant fixation
Description: Arthroscopic ACL reconstruction with implant (using hamstring tendon autograft fixed with bioscrew and endo-button)
Study: NCT02342743

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CEFALY
Study: NCT04124081

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydronidone capsules& Entecavir capsules
Description: take the Hydronidone capsule and then the entecavir capsule, and then take the last two together
Study: NCT00629434

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: diabetes education via telemedicine
Description: This arm will receive diabetes group education via telemedicine

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: diabetes education in-person
Description: In this arm the group of patients with diabetes will receive diabetes education in-person
Study: NCT00701233

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum toxin
Description: 45 units Botox injected into Carpal Tunnel once

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroid injection into Carpal Tunnel
Description: 40 mg Triamcinolone with one mL 1% lidocaine injected once into Carpal Tunnel
Study: NCT03602066

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorine Dioxide Sterilization
Description: Given via oral rinse

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given via oral rinse
Study: NCT04266665

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Dexmedetomidine 2 μg/ml will be given as bolus 1mg/kg for 10 minutes with a maintenance dose of 0.8μg/kg/h until surgery completion

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Equivalent doses for a solution containing 2mcg/ml of the tested drug calculating for a bolus 1mg/kg for 10 minutes with a maintenance dose of 0.8μg/kg/h until surgery completion
Study: NCT00092495

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V501, Gardasil, human papillomavirus (type 6, 11, 16, 18) recombinant vaccine
Description: qHPV Vaccine (20, 40, 60 or 100% dose formulation) 0.5 mL intramuscular injection given at Day 1, Month 2 and Month 6.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V501, Gardasil, human papillomavirus (type 6, 11, 16, 18) recombinant vaccine
Description: qHPV Vaccine (20, 40, 60 or 100% dose formulation) 0.5 mL intramuscular injection given at Day 1, Month 2 and Month 6.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V501, Gardasil, human papillomavirus (type 6, 11, 16, 18) recombinant vaccine
Description: qHPV Vaccine (20, 40, 60 or 100% dose formulation) 0.5 mL intramuscular injection given at Day 1, Month 2 and Month 6.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V501, Gardasil, human papillomavirus (type 6, 11, 16, 18) recombinant vaccine
Description: qHPV Vaccine (20, 40, 60 or 100% dose formulation) 0.5 mL intramuscular injection given at Day 1, Month 2 and Month 6.
Study: NCT04931186

Intervention type: OTHER
Intervention: retrospective analyis
Description: retrospective analysis of data